JOIN US FOR YOUR COFFEE BREAK
Networks of excitable cells play a fundamental role in life, from the beating heart to the conscious brain.
In the time it takes to drink your coffee, experts in the field will explain how they are using Axion's technology to better understand life's circuitry.
Pour yourself a cup of coffee and learn more about life's circuitry.
COFFEE BREAK WEBINARS
Experts in the field explain how they are using Axion's technology to better understand life's circuitry.
In our daily lives we are increasingly exposed to man-made chemicals, including pharmaceutical compounds, antimicrobials, flame retardants, food-additives, and pesticides. It is well known that nervous system function is particularly sensitive to disruption by a wide variety of compounds. Consequently, approaches to assess neurotoxicity in a high-throughput screen are required. However, neuroactivity is a complex health endpoint, and existing assays don’t cover the breadth of potential neurotoxicity-related targets. In this webinar, Dr. Marissa Kosnik (Stockholm University) in collaboration with US Environmental Protection Agency, demonstrates how measuring compound-induced changes to the spontaneous firing activity of neural cells in an MEA assay can efficiently screen for diverse chemical activities relevant to neurotoxicity, and that chemical structure may be predictive of response patterns.
Glioblastoma is a particularly aggressive form of brain cancer, and has no effective treatments. Consequently, new therapeutic approaches, such as immunotherapies, are urgently needed to improve patient outcomes. One such therapy is chimeric antigen receptor (CAR) T cell therapy, a form of targeted immunotherapy that involves the modification of a patient’s own T cells to target specific antigens expressed on the tumor cell surface. In this webinar, Dr. Lohitash Karumbaiah and Megan Logan (University of Georgia), use label-free impedance measurements to assess in real-time, the targeting potency of activated human T cells on glioma cell monolayers and demonstrate the value of using an in vitro impedance-based assay to access therapeutic CAR T-cell potency against glioblastoma.
The development of disorders such as autism and schizophrenia are thought to have their origins in the developing brain. But studying the development of the human brain is challenging due to the absence of good model. In this webinar, Prof. Alysson Muotri (UC San Diego) demonstrates that the spontaneous development of neural networks in neural organoids, commonly referred to as “mini-brains,” resembles those found during early human brain formation. The research findings covered in this webinar were published recently in the journal, Cell Stem Cell, and were featured in numerous media outlets including the New York Times and NPR.
Epilepsy is a devastating neurological disease caused by an imbalance in the electrical signals between the cells of the brain. It affects 1% of newborns and very young children. In children, 1/3 of all cases fail to respond to currently available medication. The primary challenge in the fight against epilepsy is the lack of model systems that effectively mirror what goes wrong in human patients. In this webinar, Dr. Evangelos Kiskinis (Northwestern University), demonstrates how patient-specific neurons in vitro recapitulate the neural firing patterns observed in patient EEGs in vivo. Using this platform Dr. Kiskinis hopes to be able to predict what drug would work best for each patient, removing the trial-and-error approach to epilepsy therapy.
Fragile X syndrome is the most prevalent genetic form of intellectual disability. There is no cure or treatment due in part to the complexity in the Fragile X syndrome neuronal circuitry. In this webinar, Dr. John Graef (Fulcrum Therapeutics), demonstrates how using CRISPR gene-editing and patient-derived cells Fulcrum can create the Fragile X syndrome phenotype in a dish. Moreover, this approach has enabled an estimate of the level of FMRP protein expression required to correct the observed Fragile X syndrome phenotype.
Long QT syndrome, also referred to as LQTS, is a genetic disorder which affects the repolarization of the heart after a heartbeat. This prolonged repolarization of the heart is observed as a lengthening of the QT interval in the electrocardiogram, hence the disorders name. A long QT interval can upset the careful timing of the heartbeat and trigger dangerous heart rhythms which can result in fainting, seizures, or sudden death. In this webinar, Dr. Vincenzo Macri (STEMCELL Technologies) discusses how the stem cell culture and gene editing technologies being developed by his lab can be used to recreate these patient heart beats in a dish.
Neuromuscular disorders include ALS, myasthenia gravis, and the muscular dystrophies such as Duchenne's. Collectively these disorders exceed an incidence of 1 in 3,000. Although there is a strong genetic understanding of many of these disorders, the poor translatability of animal models to humans has hindered the development of treatments for these diseases. Consequently, there is a need for a model that more faithfully recapitulates the physiology of the human neuromuscular junction. In this webinar, Dr. Elliot Swartz (UCLA) discusses how he is building a light controlled hiPSC model of a neuromuscular junction to help better understand neuromuscular disorders.
Autism, also known as autism spectrum disorder, is a range of conditions classified as neurodevelopmental disorders. Individuals diagnosed with autism show challenges with social skills, repetitive behaviors, speech and nonverbal communication. Autism is estimated to affect about 1% of people, or 62.2 million globally. The genetics of autism are complex meaning better methods are required to help understand the genetic risk factors that underlie autism. In this webinar, Dr. Michael Nestor (The Hussman Institute for Autism) discusses how studying the spontaneous firing activity of patient-derived iPSC neurons in an MEA assay is helping to build a model of autism.
Neurotoxicity is a leading cause of pharmaceutical compound attrition. Drug-induced seizures can deprive the brain of oxygen resulting in brain injury and an increased incidence of mortality. These seizures are the result of excessive and synchronous firing of cortical neurons in the brain. Microelectrode array assays have emerged as a promising tool to predict seizure risk by measuring drug-induced changes to the spontaneous firing activity of neural networks in vitro. In this webinar, Dr. Benjamin Bader (NeuroProof) discusses how artificial intelligence-based machine-learning can be applied to these neural MEA datasets to improve the prediction of seizure risk.
In our daily lives we are exposed to thousands of commercially used chemicals. Many of these chemicals are not toxic at typical exposure levels, but for thousands of chemicals, toxicological information is lacking. The National Academy of Sciences report on ‘‘Toxicity testing in the 21st century’’ highlighted the need for efficient methods to screen chemicals (e.g. insecticides) for their potential to cause toxicity. In this webinar, Dr. Lorena Saavedra (NeuCyte) discusses how measuring compound-induced changes to the spontaneous firing activity of human stem cell-derived neural cells in an MEA assay helped detect potentially harmful neurological side effects of compounds such as pyrethroid insecticides.
“Man on Fire” syndrome, also known as Inherited Erythromelalgia (IEM), is a chronic pain syndrome characterized by burning pain in the hands and feet. The chronic pain of most patients with IEM cannot be relieved by common pain killers making this disease a major unmet medical need. In this webinar, Dr. Yang Yang (Purdue University) discusses advances in the treatment of IEM using a pharmacogenomic approach. The drug responsiveness of different genetic mutations associated with IEM were probed in an in vitro Maestro MEA assay, with the results helping to predict the effective treatment of these IEM patients in the clinic.
The inability to predict a drug’s cardiovascular liability prior to clinical trials or launch has resulted in numerous costly late stage drug development failures and market withdrawals. The aim of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative is to update the existing cardiac safety testing paradigm to better evaluate arrhythmia risk. One proposed test of the CiPA panel is a microelectrode array (MEA) assay that tracks drug-induced changes to beating heart cells in a dish. In this webinar, Dr. Daniel Millard, discusses advances in arrhythmia detection to support next-generation CM-MEA assays.
Sixty-five million people world-wide suffer from epilepsy. Epilepsy is characterized by seizures, which are the result of excessive nerve activity in the brain. While treatments are available, finding the optimal medication for any patient involves a period of trial-and-error. The need to better understand the underlying causes and develop better treatments for epilepsy are clear. In this webinar, Dr. Mike Boland and Dr. K. Melodi McSweeney (Columbia University) discuss the power of utilizing genetically engineered mice to explore the neuronal networks associated with epilepsy.